Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples